The global market for CAR-T Cell Therapy Solution was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for CAR-T Cell Therapy Solution, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of CAR-T Cell Therapy Solution by region & country, by Type, and by Application.
The CAR-T Cell Therapy Solution market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CAR-T Cell Therapy Solution.
麻豆原创 Segmentation
By Company
Thermo Fisher Scientific
Q2 Solutions
Agilent Technologies
Genscript Biotech
Sino Biological
Nuowei Biotechnology
Novartis
JW Therapeutics
Sorrento Therapeutics
Gilead Sciences
Segment by Type:
CD19 CAR Cell Therapy
BCMA CAR Cell Therapy
Segment by Application
Leukemia
Lymphoma
Myeloma
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of CAR-T Cell Therapy Solution manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of CAR-T Cell Therapy Solution in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of CAR-T Cell Therapy Solution in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 麻豆原创 Overview
1.1 CAR-T Cell Therapy Solution Product Introduction
1.2 Global CAR-T Cell Therapy Solution 麻豆原创 Size Forecast
1.3 CAR-T Cell Therapy Solution 麻豆原创 Trends & Drivers
1.3.1 CAR-T Cell Therapy Solution Industry Trends
1.3.2 CAR-T Cell Therapy Solution 麻豆原创 Drivers & Opportunity
1.3.3 CAR-T Cell Therapy Solution 麻豆原创 Challenges
1.3.4 CAR-T Cell Therapy Solution 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global CAR-T Cell Therapy Solution Players Revenue Ranking (2023)
2.2 Global CAR-T Cell Therapy Solution Revenue by Company (2019-2024)
2.3 Key Companies CAR-T Cell Therapy Solution Manufacturing Base Distribution and Headquarters
2.4 Key Companies CAR-T Cell Therapy Solution Product Offered
2.5 Key Companies Time to Begin Mass Production of CAR-T Cell Therapy Solution
2.6 CAR-T Cell Therapy Solution 麻豆原创 Competitive Analysis
2.6.1 CAR-T Cell Therapy Solution 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by CAR-T Cell Therapy Solution Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CAR-T Cell Therapy Solution as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 CD19 CAR Cell Therapy
3.1.2 BCMA CAR Cell Therapy
3.2 Global CAR-T Cell Therapy Solution Sales Value by Type
3.2.1 Global CAR-T Cell Therapy Solution Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global CAR-T Cell Therapy Solution Sales Value, by Type (2019-2030)
3.2.3 Global CAR-T Cell Therapy Solution Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Leukemia
4.1.2 Lymphoma
4.1.3 Myeloma
4.1.4 Others
4.2 Global CAR-T Cell Therapy Solution Sales Value by Application
4.2.1 Global CAR-T Cell Therapy Solution Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global CAR-T Cell Therapy Solution Sales Value, by Application (2019-2030)
4.2.3 Global CAR-T Cell Therapy Solution Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global CAR-T Cell Therapy Solution Sales Value by Region
5.1.1 Global CAR-T Cell Therapy Solution Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global CAR-T Cell Therapy Solution Sales Value by Region (2019-2024)
5.1.3 Global CAR-T Cell Therapy Solution Sales Value by Region (2025-2030)
5.1.4 Global CAR-T Cell Therapy Solution Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America CAR-T Cell Therapy Solution Sales Value, 2019-2030
5.2.2 North America CAR-T Cell Therapy Solution Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe CAR-T Cell Therapy Solution Sales Value, 2019-2030
5.3.2 Europe CAR-T Cell Therapy Solution Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific CAR-T Cell Therapy Solution Sales Value, 2019-2030
5.4.2 Asia Pacific CAR-T Cell Therapy Solution Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America CAR-T Cell Therapy Solution Sales Value, 2019-2030
5.5.2 South America CAR-T Cell Therapy Solution Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa CAR-T Cell Therapy Solution Sales Value, 2019-2030
5.6.2 Middle East & Africa CAR-T Cell Therapy Solution Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions CAR-T Cell Therapy Solution Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions CAR-T Cell Therapy Solution Sales Value
6.3 United States
6.3.1 United States CAR-T Cell Therapy Solution Sales Value, 2019-2030
6.3.2 United States CAR-T Cell Therapy Solution Sales Value by Type (%), 2023 VS 2030
6.3.3 United States CAR-T Cell Therapy Solution Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe CAR-T Cell Therapy Solution Sales Value, 2019-2030
6.4.2 Europe CAR-T Cell Therapy Solution Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe CAR-T Cell Therapy Solution Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China CAR-T Cell Therapy Solution Sales Value, 2019-2030
6.5.2 China CAR-T Cell Therapy Solution Sales Value by Type (%), 2023 VS 2030
6.5.3 China CAR-T Cell Therapy Solution Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan CAR-T Cell Therapy Solution Sales Value, 2019-2030
6.6.2 Japan CAR-T Cell Therapy Solution Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan CAR-T Cell Therapy Solution Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea CAR-T Cell Therapy Solution Sales Value, 2019-2030
6.7.2 South Korea CAR-T Cell Therapy Solution Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea CAR-T Cell Therapy Solution Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia CAR-T Cell Therapy Solution Sales Value, 2019-2030
6.8.2 Southeast Asia CAR-T Cell Therapy Solution Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia CAR-T Cell Therapy Solution Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India CAR-T Cell Therapy Solution Sales Value, 2019-2030
6.9.2 India CAR-T Cell Therapy Solution Sales Value by Type (%), 2023 VS 2030
6.9.3 India CAR-T Cell Therapy Solution Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Thermo Fisher Scientific
7.1.1 Thermo Fisher Scientific Profile
7.1.2 Thermo Fisher Scientific Main Business
7.1.3 Thermo Fisher Scientific CAR-T Cell Therapy Solution Products, Services and Solutions
7.1.4 Thermo Fisher Scientific CAR-T Cell Therapy Solution Revenue (US$ Million) & (2019-2024)
7.1.5 Thermo Fisher Scientific Recent Developments
7.2 Q2 Solutions
7.2.1 Q2 Solutions Profile
7.2.2 Q2 Solutions Main Business
7.2.3 Q2 Solutions CAR-T Cell Therapy Solution Products, Services and Solutions
7.2.4 Q2 Solutions CAR-T Cell Therapy Solution Revenue (US$ Million) & (2019-2024)
7.2.5 Q2 Solutions Recent Developments
7.3 Agilent Technologies
7.3.1 Agilent Technologies Profile
7.3.2 Agilent Technologies Main Business
7.3.3 Agilent Technologies CAR-T Cell Therapy Solution Products, Services and Solutions
7.3.4 Agilent Technologies CAR-T Cell Therapy Solution Revenue (US$ Million) & (2019-2024)
7.3.5 Genscript Biotech Recent Developments
7.4 Genscript Biotech
7.4.1 Genscript Biotech Profile
7.4.2 Genscript Biotech Main Business
7.4.3 Genscript Biotech CAR-T Cell Therapy Solution Products, Services and Solutions
7.4.4 Genscript Biotech CAR-T Cell Therapy Solution Revenue (US$ Million) & (2019-2024)
7.4.5 Genscript Biotech Recent Developments
7.5 Sino Biological
7.5.1 Sino Biological Profile
7.5.2 Sino Biological Main Business
7.5.3 Sino Biological CAR-T Cell Therapy Solution Products, Services and Solutions
7.5.4 Sino Biological CAR-T Cell Therapy Solution Revenue (US$ Million) & (2019-2024)
7.5.5 Sino Biological Recent Developments
7.6 Nuowei Biotechnology
7.6.1 Nuowei Biotechnology Profile
7.6.2 Nuowei Biotechnology Main Business
7.6.3 Nuowei Biotechnology CAR-T Cell Therapy Solution Products, Services and Solutions
7.6.4 Nuowei Biotechnology CAR-T Cell Therapy Solution Revenue (US$ Million) & (2019-2024)
7.6.5 Nuowei Biotechnology Recent Developments
7.7 Novartis
7.7.1 Novartis Profile
7.7.2 Novartis Main Business
7.7.3 Novartis CAR-T Cell Therapy Solution Products, Services and Solutions
7.7.4 Novartis CAR-T Cell Therapy Solution Revenue (US$ Million) & (2019-2024)
7.7.5 Novartis Recent Developments
7.8 JW Therapeutics
7.8.1 JW Therapeutics Profile
7.8.2 JW Therapeutics Main Business
7.8.3 JW Therapeutics CAR-T Cell Therapy Solution Products, Services and Solutions
7.8.4 JW Therapeutics CAR-T Cell Therapy Solution Revenue (US$ Million) & (2019-2024)
7.8.5 JW Therapeutics Recent Developments
7.9 Sorrento Therapeutics
7.9.1 Sorrento Therapeutics Profile
7.9.2 Sorrento Therapeutics Main Business
7.9.3 Sorrento Therapeutics CAR-T Cell Therapy Solution Products, Services and Solutions
7.9.4 Sorrento Therapeutics CAR-T Cell Therapy Solution Revenue (US$ Million) & (2019-2024)
7.9.5 Sorrento Therapeutics Recent Developments
7.10 Gilead Sciences
7.10.1 Gilead Sciences Profile
7.10.2 Gilead Sciences Main Business
7.10.3 Gilead Sciences CAR-T Cell Therapy Solution Products, Services and Solutions
7.10.4 Gilead Sciences CAR-T Cell Therapy Solution Revenue (US$ Million) & (2019-2024)
7.10.5 Gilead Sciences Recent Developments
8 Industry Chain Analysis
8.1 CAR-T Cell Therapy Solution Industrial Chain
8.2 CAR-T Cell Therapy Solution Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 CAR-T Cell Therapy Solution Sales Model
8.5.2 Sales Channel
8.5.3 CAR-T Cell Therapy Solution Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Thermo Fisher Scientific
Q2 Solutions
Agilent Technologies
Genscript Biotech
Sino Biological
Nuowei Biotechnology
Novartis
JW Therapeutics
Sorrento Therapeutics
Gilead Sciences
听
听
*If Applicable.
